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Abstract
Background/objective: Mauriac  syndrome  (MS)  is  a  rare  complication  of  type  1  diabetes  mellitus
(DM1). It  is  related  to  low  insulin  concentrations  and  is  less  common  since  longer-acting  insulins
became  available.  It  is  characterized  by  hepatomegaly,  growth  and  puberty  delay,  and  the
presence of  elevated  transaminases  and  serum  lipids.  The  aim  of  this  study  was  to  describe  the
patients from  a  pediatric  diabetic  population  that  fulﬁll  the  criteria  of  MS.
Materials  and  methods:  A  retrospective  analysis  of  the  pediatric  diabetic  population  with  diag-
nostic criteria  of  MS  currently  followed  at  Hospital  de  Braga,  was  performed.
Results:  From  a  population  of  91  patients  with  DM1  18  years,  6  patients  with  the  criteria  for  MS
were identiﬁed:  5  girls,  and  1  boy.  The  age  at  presentation  was  13--17  years,  with  a  minimum
interval between  DM1  diagnosis  and  MS  criteria  of  4  years.  All  the  patients  were  prescribed
intensive  insulin  therapy  (median  daily  insulin  dose:  0.88  U/kg).  All  had  a  previous  history  of
poor glycemic  control  before  the  diagnosis  of  MS  with  glycated  hemoglobin  (HbA1c)  between
8.8 and  12.9%.  Increase  of  hepatic  enzymes  was  present  in  all  the  patients;  4  of  them  had
associated  hepatomegaly.  All  the  girls  presented  puberty  delay  and  cushingoid  features.  None
of the  patients  presented  short  stature  and  5  of  them  presented  mixed  dyslipidemia.
Conclusions:  Although  MS  is  an  ancient  entity  described  in  DM1,  it  still  exists,  particularly  in
adolescent  females.  Being  aware  of  MS  is  of  extreme  importance  since  most  of  the  clinical
features are  reversible  with  better  glycemic  control.
© 2012  SEEN.  Published  by  Elsevier  España,  S.L.  All  rights  reserved.
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Resumen
Introducción/objetivo:  El  síndrome  de  Mauriac  (SM)  es  una  complicación  rara  de  la  diabetes
mellitus  de  tipo  1  (DM1),  relacionada  con  bajas  concentraciones  de  insulina,  y  es  menos  común
desde que  están  disponibles  insulinas  de  larga  duración  de  acción.  Se  caracteriza  por  la  hep-
atomegalia,  el  retraso  del  crecimiento  y  de  la  pubertad  y  la  elevación  de  las  transaminasas  y  de
los lípidos  séricos.  El  objetivo  de  este  estudio  fue  la  descripción  de  los  pacientes  con  criterios
de SM  en  una  población  pediátrica  con  DM1.
∗ Corresponding author.
E-mail address: joanamprdias@gmail.com (J. Dias).
2173-5093/$ – see front matter © 2012 SEEN. Published by Elsevier España, S.L. All rights reserved.
246 J. Dias et al.
Material  y  métodos: Análisis  retrospectivo  de  una  población  pediátrica  diabética  atendida  en
el Hospital  de  Braga  con  criterios  diagnósticos  de  SM.
Resultados:  De  una  población  de  91  pacientes  con  DM1  menores  de  18  an˜os  fueron  identiﬁcados
6 pacientes  con  criterios  de  SM:  5  mujeres  y  un  varón.  La  edad  de  presentación  fue  de  13  a  17
an˜os con  un  intervalo  mínimo  entre  el  diagnóstico  de  DM1  y  SM  de  4  an˜os.  Todos  los  pacientes
tenían prescrita  una  terapia  insulínica  intensiva  (dosis  media  diaria:  0,88  U/kg).  Todos  tenían
una historia  previa  de  mal  control  glucémico  antes  del  diagnóstico  de  SM  con  hemoglobina
glucosilada  (HbA1c)  entre  8,8  y  12,9%.  Las  enzimas  hepáticas  estaban  aumentadas  en  todos  los
pacientes y  4  presentaban  una  hepatomegalia  asociada.  Todas  las  nin˜as  mostraban  retraso  de
la pubertad  y  un  aspecto  cushingoide.  Ningún  paciente  tenia  talla  baja  y  5  tenían  dislipidemia
mixta.
Conclusiones:  Aunque  el  SM  es  una  entidad  poco  descrita  actualmente,  aún  existe,  especial-
mente en  adolescentes  femeninas.  Identiﬁcar  el  SM  es  muy  importante  ya  que  la  mayoría  de
las alteraciones  clínicas  son  reversibles  con  mejor  control  glucémico.
© 2012  SEEN.  Publicado  por  Elsevier  España,  S.L.  Todos  los  derechos  reservados.
Introduction
Mauriac  syndrome  (MS)  is  a  rare  complication  of  type  1
diabetes  mellitus  (DM1),  characterized  by  hepatomegaly
(hepatic  glycogenosis),  puberty  and  growth  delay,  dys-
lipidemia,  transaminase  elevation  and  reduction  of  IGF1
(insulin-like  growth  factor  1).1 Cushingoid  features  may  also
be  present.2
There  may  be  different  forms  and  etiologies  involved  in
Mauriac  syndrome.  However,  there  are  common  features
noted  in  these  patients  and  with  adequate  insulin  treat-
ment  there  is  reversal  of  growth  failure  and  hepatomegaly
if  present.3
MS  is  more  common  in  children  and  adolescents  with
poor  glycemic  control  and  increased  susceptibility  of
complications,1 and  is  the  commonest  cause  of  hepatic  dys-
function  in  children  and  adolescents  with  DM1.4
Although  its  real  incidence  is  not  well-known,  due  to  the
reduced  number  of  reported  cases  in  the  literature,  equal
incidence  is  reported  in  males  and  females,  with  most  of  the
cases  occurring  in  adolescents  and  young  adults.2,5
The  authors  present  a  retrospective  analysis  of  patients
presenting  diagnostic  criteria  of  MS  from  the  type  1  diabetic
population  followed  currently  by  pediatric  endocrinology  in
Braga’s  Hospital.
Materials and methods
Cases  were  identiﬁed  by  searching  the  Pediatric  endocrinol-
ogy  DM1  database  for  conﬁrmed  clinical  and  biochemical
features  of  MS  in  patients  under  18  years  at  presentation.  A
retrospective  analysis  was  undertaken.  A  review  of  records
was  conducted  to  determine  patients’  age  at  presentation  of
DM1  and  MS,  as  well  as  glycated  hemoglobin  (HbA1c)  value,
hepatic  enzymes,  lipid  proﬁle  and  median  daily  insulin  dose
at  MS  presentation  and  follow-up  data  after  MS  diagnosis.
Data  regarding  other  complications  of  DM1  (microvascular
complications,  speciﬁcally,  retinopathy  and  nephropathy;
macrovascular  complications  and  neuropathies)  were  also
collected.  Data  research  ended  in  October  30,  2011.  The
study  was  approved  by  the  Braga’s  Hospital  pediatric
endocrinology  coordinator  and  an  informed  consent  was
signed  by  parents  or  children  legal  guardians.
Results
From  a  population  of  91  pediatric  patients  with  DM1  (fol-
lowed  from  January  2005  to  October  2011),  we  identiﬁed  6
patients  with  diagnostic  criteria  for  MS:  5  girls  and  1  boy.
Regarding  the  six  patients  with  MS,  the  median  age  at  DM1
diagnosis  was  7.8  years  (3--11  years)  and  at  MS  presentation
15.3  years  (13--17  years).  The  median  interval  between  DM1
and  MS  diagnosis  was  7.5  years  (range  4--14  years).  All  the
patients  were  under  intensive  insulin  therapy  with  a  median
daily  insulin  dose  of  0.88  U/kg.
All  had  a  previous  history  of  poor  glycemic  control
prior  to  the  MS  diagnosis  with  a  median  (glycosylated
hemoglobin)  HbA1c  concentration  at  diagnosis  of  12.3%
(range  10.5--13.5%).  The  median  HbA1c  of  the  DM1  pop-
ulation  was  8.1%  (normal  HbA1c  <  6.5%).  Non-compliance
regarding  nutritional  and  insulin  therapy  and  self-monitoring
was  a  common  feature  of  all  identiﬁed  MS  cases.
At  presentation,  the  5  girls  presented  cushingoid
features,  puberty  dysfunction  (primary  amenorrhea  in
2  patients  and  secondary  amenorrhea  in  3)  and  mixed
dyslipidemia  (high  total  cholesterol,  low  HDL[high  density
lipoprotein]  cholesterol  and  high  triglycerides:  cut-off  val-
ues  of  >200  mg/dl  for  total  cholesterol,  <  40  mg/dl  for  HDL
and  >  180  mg/dl  for  triglycerides).  The  male  patient  pre-
sented  puberty  delay  and  dyslipidemia.
Of  the  6  patients,  5  presented  hepatomegaly  (4  conﬁrmed
by  abdominal  ultrasound),  and  all  showed  transaminase
elevation:  aspartate  aminotransferase  (AST)  and  alanine
aminotransferase  (ALT)  levels  3--22-fold  above  the  upper
normal  limit.  Liver  function  tests  such  as  alkaline  phos-
phatase,  prothrombin/partial  prothrombin  time  and  total
bilirubin  were  normal,  as  well  as  thyroid  function,  IgA  and
transglutaminase  or  anti-endomysium  levels.  None  of  the
patients  presented  criteria  of  short  stature  (all  were  within
the  percentiles  P10--P75  of  expected  height  for  age  and  sex,
according  to  CDC  2010  Growth  Charts).
Clinical  and  biochemical  features  at  MS  presentation  are
shown  in  Table  1.
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After  diagnosis,  a  stronger  multidisciplinary  approach
(involving  endocrinology,  pediatrics,  nutrition,  psychology
and  psychiatry)  was  attempted  in  order  to  improve  glycemic
control.  The  mean  duration  of  follow-up  was  1.8  years
(1--3.5  years).
A  better  control  was  achieved  in  2  girls,  with  a reduction
of  HbA1c  to  concentrations  below  9%  and  an  improvement
regarding  puberty  impairment  (normalization  of  secondary
amenorrhea).  Normalization  of  transaminase  concentrations
was  achieved  only  in  one.  A  third  patient  presented  transient
improved  control  with  normalization  of  menses  and  transam-
inases.  In  another  patient,  a  normalization  of  transaminase
concentrations  was  observed  with  a modest  decrease  of
HbA1c  concentration  (from  14.5%  to  13%).  Normalization
of  transaminase  concentrations  occurred  between  4  and  12
weeks  (median  9  weeks)  after  MS  diagnosis.  In  the  sixth
patient  no  better  glycemic  control  was  achieved.  None  of
the  patients  showed  an  improvement  of  lipid  proﬁle.
The  6  patients  had  regular  ophthalmologic  evaluations
and  none  showed  signs  of  diabetic  retinopathy.  Three  of  the
6  presented  with  microalbuminuria  (>30  mg/dl  in  24  h).
Discussion
Adolescence  is  a  critical  period  of  development  charac-
terized  by  changes  in  interpersonal  roles,  responsibilities
and  identity  construction.  This  period  is  more  complex  for
adolescents  diagnosed  with  type  1  diabetes:  in  addition
to  experiencing  the  same  challenges  as  their  peers,  these
adolescents  must  deal  with  intensive  medical  regimens,
regular  clinic  appointments,  carbohydrate  calculations  and
frequent  daily  monitoring  of  blood  glucose  levels.  Although
new  insulins  and  carbohydrate  counting  approach  are  cur-
rently  available  to  facilitate  more  optimal  glycemic  control,
many  adolescents  with  type  1  diabetes  achieve  suboptimal
glycemic  control  and  in  some  cases  we  can  still  ﬁnd  MS.
The  features  of  MS  are  mostly  related  with  deﬁcient
insulinization.  Patients  can  develop  hepatomegaly  due  to
intrahepatic  glycogen  deposition;  if  these  patients  also  have
elevated  liver  enzymes,  dyslipidemia,  cushingoid  features
and  delayed  growth  or  sexual  maturation,  Mauriac  syndrome
can  be  diagnosed.4 The  literature  documents  decreased
blood  glucose  monitoring  frequency  and  deterioration  in
blood  glucose  control  and  HbA1c,  with  few  adolescents
achieving  optimal  HbA1c  values  (<7.5%).6 Although  being  an
adolescent  greater  risk,  MS  can  occur  in  any  age  if  good
metabolic  control  is  not  achieved.2
In  poorly  controlled  DM1  patients,  the  hyperglycemic
periods  followed  by  occasional  hyperinsulinization  and  the
high  cortisol  levels  as  hypoglycemia  contra-regulatory  hor-
mone  lead  to  hepatic  glycogen  storage.  In  hyperglycemic
situations,  glucose  goes  freely  into  the  hepatocyte  and  is
also  stored  as  glycogen.  On  the  other  hand,  the  deﬁcient
insulinization  due  to  poor  glycemic  control  leads  to  lipoly-
sis  and  ketone  liberation.  Ketosis  activates  cortisol  synthesis
promoting  the  release  of  fatty  acids  and  hyperglycemia.7,8 A
common  ﬁnding  in  these  patients  is  the  growth  delay  and/or
hypogonadism  secondary  to  the  high  cortisol  levels.4
The  fact  of  the  short  stature  classically  described  in  MS
not  being  reported  here  might  have  two  explanations:  the
ﬁrst  is  that  all  the  patients  were  13--17  years  old  by  the
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time  of  diagnosis,  meaning  that  they  had  already  achieved  a
normal  stature  before  the  detioration  of  metabolic  control.
The  other  reason  is  that  data  of  parents’  height  was  not
available  in  order  to  evaluate  the  expected  genetic  height,
so  that  some  might  be  in  a  normal  percentile  for  sex  and  age
but  below  their  genetic  potential.
As  in  other  series  of  cases  recently  described,  also  with
a  small  number  of  patients,  the  incidence  of  MS  seems  to
be  greater  in  adolescent  girls.  The  poor  glycemic  control
prior  to  the  diagnosis  and  the  elevated  daily  insulin  dose
are  also  described  in  other  series.4,9 These  data  suggest  the
importance  of  high  vigilance  in  promoting  patient  compli-
ance  to  insulin  dosing  rather  than  simply  increasing  insulin
dosage  in  response  to  hyperglycemia  with  subsequent  weight
gain.
With  adequate  insulin  treatment  there  is  a  reversal  of
those  features;  however,  overly  aggressive  insulin  delivery
could  result  in  rapid  deterioration  of  diabetic  retinopathy
and  nephropathy.3 The  reduction  of  hepatic  enzymes  after
achieving  reasonable  glycemic  control  suggests  that  liver
biopsy  and  other  extensive  work-up  may  be  unnecessary  in
the  management  of  similar  patients.9
The  authors  present  this  series  to  stress  the  importance
of  high  index  of  suspicion  of  MS  in  diabetic  adolescents
with  hepatomegaly,  transaminase  elevation,  dyslipidemia,
growth  or  sexual  delay  and  cushingoid  features.  A  prompt
diagnosis  and  a  multidisciplinary  approach  are  the  basis  of
the  treatment,  but  prevention  is  desirable.  Good  metabolic
control  allows  improving  liver  function  tests  as  well  as
a  reduction  of  the  probability  of  developing  other  dia-
betic  complications  related  to  persistent  hyperglycemia.
As  this  series  shows,  adolescents  and  especially  females
are  more  vulnerable  to  this  disease  and,  due  to  their
bio-psycho-social  proﬁle,  therapeutic  adhesion  is  not  easy
to  achieve,  despite  new  insulin  treatments  and  dietary
approach.
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